Myocardial stunning following combined modality combretastatin-based chemotherapy: Two case reports and review of the literature

Clinical Cardiology

Volumn 32, Issue 12, 2009, Pages

  Bhakta, Shyam ^a   Flick, Susan M ^a   Cooney, Matthey M ^a   Greskovich, John F ^b   Gilkeson, Robert C ^a   Remick, Scot C ^c   Ortiz, Jose ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c WEST VIRGINIA UNIVERSITY HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COMBRETASTATIN; DOXORUBICIN; TROPONIN I;

AGED; AKINESIA; ANAPLASTIC CARCINOMA; ANGIOCARDIOGRAPHY; ARTICLE; CASE REPORT; DISEASE COURSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HEART LEFT VENTRICLE CONTRACTION; HUMAN; MULTIMODALITY CANCER THERAPY; NAUSEA; QT PROLONGATION; STUNNED HEART MUSCLE; T WAVE INVERSION; TAKOTSUBO CARDIOMYOPATHY; THYROID CARCINOMA; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIBENZYLS; CARCINOMA; DIAGNOSTIC IMAGING; ELECTROCARDIOGRAM PATTERN; FEMALE; HUMANS; MYOCARDIAL STUNNING; THYROID NEOPLASMS; TROPONIN I;

EID: 74849103445     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20685     Document Type: Article

References (17)

1. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002;62:3408-3416.
2. Wittstein IS, Thiemann DR, Lima JA, et al.Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress. N Engl J Med. 2005;352:539-548.
3. Mayer SA, Lin J, Homma S, et al. Myocardial injury and left ventricular performance after subarachnoid hemorrhage. Stroke. 1999;30:780-786.
4. Bybee KA, Prasad A, Barsness GW, et al. Clinical Characteristics and Thrombolysis in Myocardial Infarction Frame Counts in Women With Transient Left Ventricular Apical Ballooning Syndrome. Am J Cardiol. 2004;94:343-346.
5. Tsuchihashi K, Ueshima K, Uchida T, et al. Transient Left Ventricular Apical Ballooning Without Coronary Artery Stenosis: A Novel Heart Syndrome Mimicking Acute Myocardial Infarction. J Am Coll Cardiol. 2001;38:11-18.
6. Mann DL, Kent RL, Parsons B, et al. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790-804.
7. Ako J. Transient left ventricular apical ballooning without coronary artery stenosis: a form of stunning-like phenomenon? J Am Coll Cardiol. 2002;39:4.
8. Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinicaland pharmacokinetic results. J Clin Oncol. 2003;21:2815-2822.
9. Dark GG, Hill SA, Prise VE, et al. Combretastatin A4. An agent that displays potent and selective toxicity towards tumour vasculature. Cancer Res. 1997;57:1829-1834.
10. Cooney MM, Radivoyevitch T, Dowlati A, et al. Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res. 2004;10:96-100.
11. Anderson HL, Yap JT, Miller MP, et al. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol. 2003;21: 2823-2830.
12. Iyer S, Chaplin DJ, Rosenthal DS, et al. Induction of apoptosis in proliferating human endothelial cells by the tumorspecific antiangiogenesis agent, combretastatin A-4. Cancer Res. 1998;58:4510-4514.
13. Grosios K, Loadman PM, Swaine DJ, et al. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res. 2000;20:229-234.
14. Murata R, Siemann DW, Overgaard J, et al. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother and Oncol. 2001;60:155-161.
15. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms tomanagement. Prog Cardiovasc Dis. 2007;49(5):330-352.
16. Robert J. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls. Cell Biol Toxicol. 2007;23(1):27-37.
17. Outomuro D, Grana DR, Azzato F, et al. Adriamycin-induced myocardial toxicity: new solutions for an old problem? Int J Cardiol. 2007;117(1):6-15.